Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.
Lead Product(s): Foslinanib,Sorafenib
Therapeutic Area: Oncology Product Name: CVM-1118
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Bora Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 27, 2022